Get the Stockscreener App
12.81
10.23%
-1.46
Beta Bionics Inc stock is traded at $12.81, with a volume of 1.89M.
It is down -10.23% in the last 24 hours and down -18.25% over the past month.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
See More
Previous Close:
$14.27
Open:
$13.99
24h Volume:
1.89M
Relative Volume:
2.08
Market Cap:
$570.84M
Revenue:
$110.24M
Net Income/Loss:
$-66.44M
P/E Ratio:
-8.4773
EPS:
-1.5111
Net Cash Flow:
$-61.12M
1W Performance:
-19.18%
1M Performance:
-18.25%
6M Performance:
-7.38%
1Y Performance:
-23.70%
1-Day Range:
$12.79
$14.28
1-Week Range:
$12.79
$16.44
52-Week Range:
$8.80
$32.71
Beta Bionics Inc Stock (BBNX) Company Profile
Name
Beta Bionics Inc
Sector
Industry
Phone
949-427-7785
Address
11 HUGHES, IRVINE
Compare BBNX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBNX
Beta Bionics Inc
|
12.81 | 712.54M | 110.24M | -66.44M | -61.12M | -1.5111 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Beta Bionics Inc Stock (BBNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | UBS | Buy |
| Jan-27-26 | Initiated | TD Cowen | Hold |
| Jan-09-26 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-21-25 | Resumed | Stifel | Buy |
| Oct-01-25 | Upgrade | Goldman | Neutral → Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| Jun-12-25 | Initiated | Lake Street | Buy |
| May-30-25 | Initiated | Goldman | Neutral |
| May-30-25 | Initiated | Wolfe Research | Outperform |
| Feb-24-25 | Initiated | BofA Securities | Buy |
| Feb-24-25 | Initiated | Lake Street | Buy |
| Feb-24-25 | Initiated | Leerink Partners | Outperform |
| Feb-24-25 | Initiated | Piper Sandler | Overweight |
| Feb-24-25 | Initiated | Stifel | Buy |
| Feb-20-25 | Initiated | Ladenburg Thalmann | Neutral |
| Feb-20-25 | Initiated | Robert W. Baird | Neutral |
View All
Beta Bionics Inc Stock (BBNX) Latest News
UBS Adjusts Price Target on Beta Bionics to $22 From $24, Maintains Buy Rating - marketscreener.com
Beta Bionics Inc (BBNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Beta Bionics, Inc. Revenue Breakdown – NASDAQ:BBNX - TradingView
Beta Bionics Inc (BBNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Beta Bionics (BBNX) Stock Fair Value Falls As Medtech Reset Tempers iLet And Mint Optimism - Yahoo Finance
Beta Bionics Inc (BBNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beta Bionics Inc (BBNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Beta Bionics Inc (BBNX) Institutional Confidence - TradingKey
Beta Bionics Inc (BBNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Beta Bionics (BBNX) sees 6.9% stake reported by Divisadero Street group - Stock Titan
BBNX|Beta Bionics Inc|Price:16.097|Chg%:+0.247 - TradingKey
BBNX|Beta Bionics Inc|Price:16.140|Chg%:+0.290 - TradingKey
Beta Bionics Inc (BBNX) Balance Sheet - TradingKey
BBNX|Beta Bionics Inc|Price:16.330|Chg%:+0.200 - TradingKey
Beta Bionics (BBNX) Edges Higher as Investors Eye Key Resistance LevelPercent Below MA - dars.gov.et
BBNX Maintained by Goldman Sachs -- Price Target Raised to $19.0 - GuruFocus
Goldman Sachs Maintains Beta Bionics(BBNX.US) With Buy Rating, Raises Target Price to $19 - Moomoo
If You Invested $1,000 in Beta Bionics, Inc. (BBNX) - Stock Titan
Beta Bionics Price Target Raised to $22.00/Share From $18.00 by Truist Securities - Moomoo
Truist Raises Price Target on Beta Bionics to $22 From $18, Keeps Buy Rating - Moomoo
BBNX Shareholder Alert: Robbins LLP Reminds Beta Bionics, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fiduciary Duties to Shareholders - AOL.com
Beta Bionics (BBNX) Edges Higher, Testing Key Resistance After Positive MomentumTRIN Signal - dars.gov.et
ETFs Investing in Beta Bionics, Inc. Stocks - TradingView
Price to earnings forward of Beta Bionics, Inc. – NASDAQ:BBNX - TradingView
Price to book forward of Beta Bionics, Inc. – NASDAQ:BBNX - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
BBNX PE Ratio & Valuation, Is BBNX Overvalued - Intellectia AI
Beta Bionics CFO Stephen Feider sells $170k of BBNX stock By Investing.com - Investing.com South Africa
Beta Bionics CFO Stephen Feider sells $170k of BBNX stock - Investing.com
Form 4 Beta Bionics Inc For: 2 July By Investing.com - Investing.com Canada
CFO trades 10,000 Beta Bionics (BBNX) shares under Rule 10b5-1 plan - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Beta Bionics, Inc. (BBNX) And Encourages Investors to Connect - The National Law Review
BBNX Forecast — Price Target — Prediction for 2027 - TradingView
Beta Bionics to announce Q2 2026 financial results on July 29 - scanx.trade
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders - PR Newswire
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026 - The Manila Times
Beta Bionics sets July 29 call for Q2 2026 results - Stock Titan
Beta Bionics (BBNX) CFO sells 10,000 shares under 10b5-1 trading plan - Stock Titan
Beta Bionics: Some Stabilization In Sight (NASDAQ:BBNX) - Seeking Alpha
Beta Bionics, Inc. (BBNX) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
Form 144 Beta Bionics For: 29 June By Investing.com - Investing.com Nigeria
BBNX (NASDAQ: BBNX) notice: proposed sale of 4,896 shares on 06/29/2026 - Stock Titan
Beta Bionics, Inc.(NasdaqGM: BBNX) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Beta Bionics, Inc.(NasdaqGM: BBNX) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Law firm investigates Beta Bionics for possible misleading growth disclosures affecting investors. - Pluang
Beta Bionics, Inc.(NasdaqGM:BBNX) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Beta Bionics, Inc.(NasdaqGM: BBNX) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Form 144 Beta Bionics For: 26 June By Investing.com - Investing.com Australia
Form 4 Beta Bionics Inc For: 25 June By Investing.com - Investing.com Australia
BBNX (NASDAQ) insider notice: 5,104 option shares proposed for resale 06/26/2026 - Stock Titan
Beta Bionics Inc Stock (BBNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beta Bionics Inc Stock (BBNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Feider Stephen | Chief Financial Officer |
Jun 29 '26 |
Option Exercise |
5.10 |
4,896 |
24,970 |
170,827 |
| Feider Stephen | Chief Financial Officer |
Jun 26 '26 |
Sale |
17.05 |
5,104 |
87,006 |
165,931 |
| Feider Stephen | Chief Financial Officer |
Jun 29 '26 |
Sale |
17.03 |
4,896 |
83,381 |
165,931 |
1.04%
11.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):